Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00723554 · ClinicalTrials.gov registry record · Phase 3
Iloprost Power Disc-15 in Pulmonary Arterial Hypertension
A Phase 3 study, sponsored by Actelion.
- Terminated
- Registry status
- Phase 3
- Development phase
- 63
- Enrollment target
NCT00723554: Clinical Trial Phase 3 study, sponsored by Actelion.
NCT00723554 is a Phase 3 study that was terminated before completion, run by Actelion. The registered enrollment target is 63 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00723554, a Phase 3 study, was terminated before completion, sponsored by Actelion.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 63 participants
- Enrollment target
Study Summary
A Phase IIIb, Multicenter, Open-Label Study of Patients With Pulmonary Arterial Hypertension Treated With Iloprost(Inhalation)Evaluating Safety and Inhalation Times When Converting From Power Disc-6 to Power Disc-15 With the I-neb® Adaptive Aerosol Delivery® System (I-neb® AAD®)
Primary Outcome
Number of patients reporting at least one treatment-emergent AE/Serious AE
Interventions
- DRUG Iloprost PD-6
- DRUG Iloprost PD-15
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2008-07 |
| Est. Completion | 2011-04 |
| Phase | Phase 3 |
Why NCT00723554 stopped before completion
NCT00723554 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 2 interventions - of which Iloprost PD-6 is the first listed.
NCT00723554 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00723554 about?
NCT00723554 is a clinical study titled "Iloprost Power Disc-15 in Pulmonary Arterial Hypertension". A Phase IIIb, Multicenter, Open-Label Study of Patients With Pulmonary Arterial Hypertension Treated With Iloprost(Inhalation)Evaluating Safety and Inhalation Times When Converting From Power Disc-6 to Power Disc-15 With the I-neb® Adaptive Aerosol Delivery® System (I-neb® AAD®)
What is the current status of trial NCT00723554?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 63 participants. The study started on 2008-07. Estimated completion is 2011-04.
What interventions are being tested in trial NCT00723554?
The interventions under investigation include: Iloprost PD-6 (DRUG), Iloprost PD-15 (DRUG).
Who is sponsoring clinical trial NCT00723554?
This trial is sponsored by Actelion, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00723554's enrollment target sits among peer trials
63 1800th of 2000 higher than 199 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia